Company intelligence / Profile preview

Promedius

Ownership: Private
Development stage: Commercial

Overview

Promedius has developed an AI-powered solution that analyzes chest X-rays to assess osteoporosis risk, achieving a world-leading AUC of 0.94. The product received regulatory clearance from the Korean Ministry of Food and Drug Safety in 2025 and has been designated as an innovative medical device. Clinical validation includes collaborations with major hospitals and presentations at international conferences

Therapeutic areas: Metabolic DisordersEndocrinologyRheumatology
Modalities: Device (AI-based diagnostic software)
Industry: Medical Imaging

Drug pipeline

1 asset

PROS CXR: OSTEO

Commercial

Indications: Osteoporosis

Partnerships

Major DXA equipment manufacturersGlobal pharmaceutical companies specializing in osteoporosis treatmentsMassachusetts General HospitalPenn State HealthSeoul National University HospitalKorean Society of SarcopeniaInternational Osteoporosis Foundation (IOF)PRECCO consortium with WHO, IOF, ESCEO

Beyond the preview

Go deeper on Promedius.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Promedius.

Explore the full profile